HOMEVULNERABILITIESCVE-2026-25172
HIGH

CVE-2026-25172

CWE-122Published: March 10, 2026· Updated: Mar 13, 2026

8.0
CVSS v3.1
EPSS:0.09%probability of exploitation in 30 daysPercentile:24.6th

Official Description

Integer overflow or wraparound in Windows Routing and Remote Access Service (RRAS) allows an authorized attacker to execute code over a network.

NVD Source

Technical Analysis

CVE-2026-25172 can be exploited remotely over the network without requiring physical or adjacent access, significantly expanding the attack surface for threat actors.

Exploitation requires low privileges, which limits the exposure to scenarios where an attacker has already gained initial access.

A successful exploit results in complete confidentiality breach (data exposure), full integrity compromise (data manipulation), availability disruption (denial of service), with a CVSS base score of 8.0.

CVSS v3.1 Vector Breakdown

Exploitability
Attack VectorNetwork
Attack ComplexityLow
Privileges Req.Low
User InteractionRequired
ScopeUnchanged
Impact
ConfidentialityHigh
IntegrityHigh
AvailabilityHigh
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:U/C:H/I:H/A:H

Affected Vendors & Products

Microsoft6 products
windows server 2012windows server 2016windows server 2019windows server 2022windows server 2022 23h2windows server 2025
Source: NVD CPE · 7 total CPE entries

Exploit & PoC Resources

NO KNOWN EXPLOITNo public exploit confirmed at this time
External links open in a new tab. Always verify in a controlled environment before use.

Official Patches & Advisories

All References (1)

Quick Facts

CVE IDCVE-2026-25172
CVSS Score8.0 / 10
SeverityHIGH
WeaknessCWE-122
CISA KEVNo
EPSS (30d)0.09%
Affected1 vendor
PublishedMar 10, 2026

Related CVEs (CWE-122)

Recommended Actions

  • Apply vendor patches immediately
  • Monitor CVE-2026-25172 in threat intel feeds
  • Review IDS/IPS signatures for exploitation attempts
Data sourced from NVD (NIST), CISA KEV, and EPSS (FIRST). Analysis generated by CTIWATCH.COM. CVE data is provided under the NVD usage policy.